SCHEMBL13005771

SCHEMBL13005771

O=C(O)/C=[N+](\[O-])Cc1cccc(I)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
THPO P40225 1/20 0.38
RAB9A P51151 1/20 0.38
HIF1A Q16665 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
IDO1 P14902 2/20 0.38
LMNA P02545 1/20 0.37
PMP22 Q01453 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FAAH O00519 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
HTR2A P28223 2/20 0.34
MAPK8 P45983 1/20 0.34
HTR2C P28335 1/20 0.33
HTR7 P34969 1/20 0.33
HTR6 P50406 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6045415 1.00 CYP1A2 (0.38) CYP1A2CYP2D6CYP2C19THPORAB9A
SCHEMBL6045414 1.00 CYP1A2 (0.38) CYP1A2CYP2D6CYP2C19THPORAB9A
SCHEMBL12530396 0.82 TRPV1 (0.40) CYP1A2CYP2D6CYP2C19THPORAB9A
SCHEMBL5873407 0.81 CES2 (0.45) CYP2D6CYP2C19LMNA
SCHEMBL5873408 0.81 CES2 (0.45) CYP2D6CYP2C19LMNA
SCHEMBL6045232 0.80 TPMT (0.36) IDO1FAAH
SCHEMBL13005770 0.80 TPMT (0.36) IDO1FAAH
SCHEMBL6045235 0.80 TPMT (0.36) IDO1FAAH
SCHEMBL5166757 0.72 TRPV1 (0.44) CYP1A2CYP2D6CYP2C19THPORAB9A
SCHEMBL13005774 0.71 CYP1A2 (0.41) CYP1A2CYP2D6CYP2C19IDO1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed